Genetic models with IL-17 receptor deficiency show reduced epidermal thickening and papilloma formation, while topical PLK4 inhibition alone does not significantly alter disease progression, highlighting a complex interaction between immune and mitotic pathways in skin cancer that needs to be further elucidated [20]. The gene discussed is PLK4; the disease is skin cancer.